Brainstorm Cell Therapeutics (BCLI)

Brainstorm Cell Therapeutics Financial Statements


Brainstorm Cell Therapeutics Financial Overview

Brainstorm Cell Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.657; its P/E ratio is -6.39; Brainstorm Cell Therapeutics is scheduled to report earnings on October 19, 2022, and the estimated EPS forecast is $-0.18. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Mar 22Dec 21Sep 21Jun 21
Income Statement
Total Revenue$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit$ ―$ ―$ ―$ ―$ ―
EBIT$ -7.59M$ -5.47M$ -6.21M$ -5.28M$ -6.12M
EBITDA$ -7.52M$ -5.40M$ -6.14M$ -5.21M$ -6.06M
Net Income Common Stockholders$ -7.04M$ -5.36M$ -6.19M$ -5.34M$ -6.27M
Balance Sheet
Cash, Cash Equivalents and Short-Term Investments$ 12.24M$ 18.40M$ 22.09M$ 27.81M$ 28.81M
Total Assets$ 18.96M$ 25.79M$ 29.28M$ 34.54M$ 42.23M
Total Debt$ 1.50M$ 4.72M$ 5.10M$ 5.39M$ 5.67M
Net Debt$ -10.74M$ -13.67M$ -17.00M$ -22.41M$ -23.14M
Total Liabilities$ 11.11M$ 11.30M$ 9.94M$ 9.61M$ 12.06M
Stockholders Equity$ 7.85M$ 14.49M$ 19.34M$ 24.93M$ 25.98M
Cash Flow
Free Cash Flow$ -6.15M$ -3.70M$ -5.54M$ -6.70M$ -5.36M
Operating Cash Flow$ -6.13M$ -3.69M$ -5.51M$ -6.46M$ -5.33M
Investing Cash Flow$ -12.00K$ -17.00K$ -1.30M$ 1.70M$ -39.00K
Financing Cash Flow$ 0.00$ 0.00$ -34.00K$ -106.00K$ 0.00
Currency in USD

Brainstorm Cell Therapeutics Earnings and Revenue History

Brainstorm Cell Therapeutics Debt to Assets

Brainstorm Cell Therapeutics Cash Flow

Brainstorm Cell Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis